K. Park

2.6k citations

88 papers · 1.9k · 1 hit paper · h-index 20

Impact in

Pulmonary and Respiratory Medicine top 2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies

Papers in

Pulmonary and Respiratory Medicine 70
- Lung Cancer Treatments and Mutations 66
- Lung Cancer Diagnosis and Treatment 5
Oncology 23
- Cancer Immunotherapy and Biomarkers 19
- Lung Cancer Research Studies 3
- Cancer Treatment and Pharmacology 1

Co-authors: Tony S.K. Mok (17 shared papers)Kenneth John O'Byrne (11 shared papers)James Chih‐Hsin Yang (12 shared papers)D.-W. Kim (7 shared papers)K.H. Lee (8 shared papers)Michael Joseph Boyer (13 shared papers)Luis G Paz-Ares (17 shared papers)Vera Hirsh (8 shared papers)
Journals: Annals of Oncology (59 papers)Journal of Thoracic Oncology (17 papers)European Journal of Cancer (3 papers)Lung Cancer (2 papers)ESMO Open (2 papers)
Partner nations: South Korea United States Spain

In The Last Decade

K. Park

85 papers receiving 1.8k citations

K. Park's Hit Papers

align trajectories log scale

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial 2017 · 439 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2017 Annals of Oncology

Peers

Countries citing papers authored by K. Park

Since Specialization

Citations

This map shows the geographic impact of K. Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Park more than expected).

Fields of papers citing papers by K. Park

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Park. The network helps show where K. Park may publish in the future.

Co-authors

The 25 scholars most cited alongside K. Park, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with K. Park Line = papers co-authored together K. Park links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 88 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial Annals of Oncology ·Luis G Paz-Ares, E.H. Tan, Kenneth John O'Byrne, L. Zhang, Vera Hirsh, Michael Joseph Boyer, James Chih‐Hsin Yang, Tony S.K. Mok Hit paper breakdown →	2017	439
2	ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer Annals of Oncology ·David Planchard, Niels Reinmuth, С. В. Орлов, Jürgen R. Fischer, Shunichi Sugawara, Sławomir Mańdziuk, Diego Márquez-Medina, Silvia Novello	2020	131
3	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial Annals of Oncology ·Martin Schüler, James Chih‐Hsin Yang, K. Park, Jie‐Hyun Kim, Jaafar Bennouna, Y.-M. Chen, CHRISTOS CHOUAID, Filippo de Marinis	2015	114
4	Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study European Journal of Cancer ·Joachim von Pawel, Rodolfo Eduardo Bordoni, Miyako Satouchi, Louis Fehrenbacher, Manuel Cobo, Ji‐Youn Han, Toyoaki Hida, Denis Moro‐Sibilot	2018	90
5	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS Annals of Oncology ·K. Park, Johan Vansteenkiste, Ki Hyeong Lee, G. Pentheroudakis, Caicun Zhou, Kumar Prabhash, Takashi Seto, P.J. Voon	2020	85
6	Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy Annals of Oncology ·Bruno P. Coudert, Tudor–Eliade Ciuleanu, K. Park, Yi-Long Wu, Giuseppe Giaccone, Wolfram Brugger, P. Gopalakrishna, Federico Cappuzzo	2011	83
7	A randomized trial of heparin plus ursodiol vs heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation Bone Marrow Transplantation ·SH Park, MH Lee, Hyunwoo Lee, Kihyun Kım, W. S. Kim, CW Jung, YH Im, SS Yoon	2002	78
8	Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study Annals of Oncology ·Taofeek Kunle Owonikoko, H.R. Kim, Ramaswamy Govindan, Neal Ready, Martin Reck, Solange Peters, Shaker R. Dakhil, Alejandro Navarro	2019	74
9	Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma Annals of Oncology ·Jiyeon Lee, Cheolwon Suh, Hye Jin Kang, Baek‐Yeol Ryoo, Jooryung Huh, Young Hyeh Ko, Hyeon‐Seok Eom, Kihyun Kım	2008	63
10	Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC Annals of Oncology ·Fabrice Barlési, K. Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz Mirosław Kowalski, Diego Luigi Cortinovis	2016	59
11	Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study Annals of Oncology ·D.H. Lee, S.-W. Kim, Cheolwon Suh, J.-S. Lee, J.-S. Lee, Jeong Hyun Lee, S.-J. Lee, Baek‐Yeol Ryoo	2007	51
12	Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study Lung Cancer ·Robert Pirker, J. R. Pereira, Aleksandra Szczęsna, Joachim von Pawel, Maciej Jerzy Krzakowski, Rodryg Ramlau, Ihor O. Vynnychenko, K. Park	2012	51
13	LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722 Annals of Oncology ·Tony S.K. Mok, Kazuhiko Nakagawa, K. Park, Y. Ohe, Nicolas Girard, H.R. Kim, Yi-Long Wu, J.F. Gainor	2022	47
14	1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose Journal of Thoracic Oncology ·K. Park, J.-S. Lee, J. Y. Han, K.H. Lee, Jee Hyun Kim, E.K. Cho, Jungwon Cho, Young Joo Min	2016	37
15	Aspiration: First-Line Erlotinib (E) Until and Beyond Recist Progression (Pd) in Asian Patients (Pts) with Egfr Mutation-Positive (Mut+) Nsclc Annals of Oncology ·K. Park, Myung‐Ju Ahn, Chong‐Jen Yu, S. Kim, Meng‐Chih Lin, Virote Sriuranpong, C.-M. Tsai, J. Lee	2014	33
16	A Randomized Phase (PH) 2 Study with Exploratory Biomarker Analysis of Ficlatuzumab (F) A Humanized Hepatocyte Growth Factor (HGF) Inhibitory MAB in Combination with Gefitinib (G) Versus G in Asian Patients (PTS) with Lung Adenocarcinoma (LA) Annals of Oncology ·Tony S.K. Mok, K. Park, Sarayut Lucien Geater, Shefali Agarwal, Marc Credi, K. McKee, William J. Slichenmyer, E.H. Tan +2 others	2012	31
17	14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR) European Journal of Cancer ·Johan Vansteenkiste, Lou Fehrenbacher, Alexander Spira, Julien Mazières, K. Park, D.A. Smith, Angel Artal, Conrad R. Lewanski	2015	31
18	1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study Annals of Oncology ·N. B. Leighl, Catherine A. Shu, Anna Rachel Minchom, Enriqueta Felip, Sophie Cousin, Byoung Chul Cho, K. Park, J-Y. Han	2021	28
19	Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis Annals of Oncology ·Kaoru Kubota, Y. Ichinose, Giorgio V. Scagliotti, David Robert Spigel, Jae‐Hoon Kim, Tetsu Shinkai, S-W. Kim, Te‐Chun Hsia	2014	24
20	P1.01-81 Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789 Journal of Thoracic Oncology ·Greg J. Riely, Rina Hui, David Paul Carbone, K. Park, Marion Carrigan, Xiaoyan Xu, T. Dang, James Chih‐Hsin Yang	2018	20

About K. Park

K. Park is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Urology, Hematology and Pathology and Forensic Medicine, having authored 88 papers that have together received 1.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (66 papers), Cancer Immunotherapy and Biomarkers (19 papers), Lung Cancer Diagnosis and Treatment (5 papers), Lung Cancer Research Studies (3 papers), Chemotherapy-induced cardiotoxicity and mitigation (1 paper), Lymphoma Diagnosis and Treatment (1 paper), Cancer Treatment and Pharmacology (1 paper) and Congenital Anomalies and Fetal Surgery (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.2k citations), Oncology (499 citations), Pathology and Forensic Medicine (73 citations), Hematology (55 citations) and Hepatology (23 citations). K. Park has collaborated with scholars based in South Korea, United States and Spain. Frequent co-authors include Tony S.K. Mok, Kenneth John O'Byrne, James Chih‐Hsin Yang, D.-W. Kim, K.H. Lee, Michael Joseph Boyer, Luis G Paz-Ares, Vera Hirsh, L. Zhang and Angela Märten. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, European Journal of Cancer, Lung Cancer and ESMO Open.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

K. Park

Impact in

Papers in i

In The Last Decade

K. Park

K. Park's Hit Papers

Peers

Countries citing papers authored by K. Park

Fields of papers citing papers by K. Park

All Works

About K. Park

Explore authors with similar magnitude of impact

Papers in